Skip to content

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Learn more

.

Founders

Dedicated to giving cancer patients better answers than “maybe”

Canada’s national nuclear laboratory

As Canada’s premier nuclear science and technology laboratory and working under the direction of Atomic Energy of Canada Limited (AECL), CNL is a world leader in the development of innovative nuclear science and technology products and services.

Guided by an ambitious corporate strategy – Vision 2030, CNL fulfills three strategic priorities of national importance – restoring and protecting the environment, advancing clean energy technologies, and contributing to the health of Canadians and people worldwide.

By leveraging the assets owned by AECL, CNL also serves as the interface between government, the nuclear industry, the broader private sector and the academic community. CNL works in collaboration with all these sectors to advance innovative Canadian products and services for real-world use, including clean energy, cancer treatments and other therapies, non-proliferation technologies and waste management solutions.

.

Isotope Technologies Munich

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply.

With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules.

By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

.

Actineer Quotes

.

Our joint venture Actineer has been launched with the overall goal to ensure access to Ac-225 as a next generation radioisotope through an innovative technology.
With the foundation of Actineer we have committed us to establish a reliable, long term and substantial production of Ac-225 in high quality standards.
This Canada based company will facilitate ground breaking research activities leading to novel cancer treatments urgently needed by many patients worldwide.

Andreas Benischke, COO of Actineer
.

Two companies with long and distinguished histories of delivering medical isotopes to the global market have come together to help realize the potential that Ac-225-based radiopharmaceuticals’ promise. CNL has been fostering the Ac-225 market for years. The creation of the joint venture with ITM will accelerate advancing the technology needed to produce large quantities.

Ram Mullur, President of Actineer
.

It is our role to drive nuclear innovation in Canada, to bring private and public expertise together to spark these new initiatives that will ultimately benefit the health of Canadians and bring new jobs to Canada. We are building on decades of Canada’s world-leading isotope innovation, and have found the key to success is collaboration, partnership, and strong leadership. We are pleased to support the joint venture between CNL and ITM with shared values to bring this potentially lifesaving therapy to the world.

Fred Dermarkar, President and 
CEO of AECL
.

Targeted alpha therapies based on Actinium-225 are gaining increasing importance in addition to the well-established beta emitters such as our highly-pure non-carrier-added (n.c.a.) Lutetium-177. Joining forces with CNL provides us the opportunity to extend our therapeutic portfolio as we continue striving to meet the needs of healthcare professionals and cancer patients worldwide.

Steffen Schuster, ITM CEO
.

Together with ITM, CNL has already made significant process towards our goal of bringing a next-generation medical isotope to the world market. With the launch of Actineer, we are poised to establish a reliable and large-scale supply of Ac-225 that we believe will unlock ground-breaking new cancer treatments. The entire team at CNL looks forward to applying their radiochemical expertise to the development of the new production process for Actinium-225 within this joint venture.

Joe McBrearty
.

Actinium-225 is a potent radionuclide utilized in targeted alpha therapies and holds great potential in the greater landscape of radionuclide therapy. Targeted alpha therapy with Actinium-225 will facilitate patient care in nuclear medicine by bringing new treatment opportunities to those who need it in addition to combining Radiopharmaceutical therapy possibilities with the established Lutetium-177. The expertise that ITM and CNL bring together is unique and essential for meeting the escalating demand for Actinium-225 across various applications.

Dr. Sebastian Marx, CBO of ITM